CAROLINA-CARMELINA-Asia-analysis

Cardiovascular and renal safety profile of linagliptin demonstrated in Asian adults with type 2 diabetesIn a sub-analysis of the CAROLINA ® cardiovascular outcome trial, linagliptin demonstrated no increased cardiovascular risk versus glimepiride in Asian adults with type 2 diabetes and high cardiovascular risk1In addition, a sub-analysis of the CARMELINA ® cardiovascular outcome trial demonstrated a similar cardiovascular and renal safety profile for linagliptin versus placebo in Asian adults with type 2 diabetes and high cardiorenal risk2 
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news